Tyzeka Priced Higher Than Epivir, But Lower Than Other Competitors

Novartis/Idenix' newly approved hepatitis B drug Tyzeka (telbivudine) will enter the market at a significantly higher price than GlaxoSmithKline's Epivir HBV (lamivudine), but at a discount compared to other competing oral HBV medications